After 945 days of litigation in the Eastern District of California, Better Meat Company’s declaratory judgment action against Emergy, Inc., Bond Capital Management LP, and investor Paul Vronsky concluded on July 19, 2024, with a stipulated dismissal with prejudice following a confidential global settlement. The case centered on U.S. Patent No. 11,058,137 B2, which covers mycoprotein-related technology embodied in Emergy’s flagship Rhiza product. The parties executed their settlement agreement on July 17, 2024, resolving all claims, counterclaims, and defenses without a judicial determination on the merits.

This case is a critical reference point for food technology companies navigating IP disputes in the alternative protein sector — one of the most rapidly patented spaces in food science. The involvement of a venture capital firm and individual investor as named defendants, alongside the declaratory judgment posture of the plaintiff, signals aggressive pre-litigation IP positioning that R&D-driven food tech companies and their investors must understand when commercializing novel protein technologies.

Case Overview

The Parties

The Patent at Issue

U.S. Patent No. 11,058,137 B2 covers methods and compositions related to mycoprotein production — specifically the cultivation and processing of fungal biomass to yield high-protein food ingredients suitable for whole-cut meat alternatives. The patent’s claims address key aspects of the fermentation process, biomass structure, and resulting product characteristics that give mycoprotein its meat-like texture. In practical terms, this patent protects the core manufacturing approach behind products like Rhiza, which competes in the rapidly expanding alternative protein ingredient market.

• • US11058137B2

Legal Representation

Plaintiff Counsel: BraunHagey & Borden LLP (lead: Amy Senia)
Defendant Counsel: Finnegan Henderson Farabow Garrett & Dunner, LLP (lead: David Mroz , PHV)

Litigation Timeline & Procedural History

The case was filed on December 17, 2021, in the U.S. District Court for the Eastern District of California — a venue often selected by Northern California-area food and agri-tech companies due to its geographic proximity and relatively predictable docket management. The choice of a first-instance district court proceeding rather than PTAB or ITC reflects a strategy focused on declaratory judgment of non-infringement or invalidity, using federal district court’s broader discovery and remedial jurisdiction to resolve the commercial dispute comprehensively, including the unusual step of naming investor entities as co-defendants.

The litigation ran for approximately 945 days — roughly two and a half years — before resolving through a negotiated global settlement rather than a dispositive motion or trial verdict. The stipulated dismissal with prejudice under FRCP 41(a)(1)(A)(ii) confirms that the settlement is final and binding, precluding any re-litigation of these claims between the parties. The confidential nature of the settlement agreement means specific financial terms, licensing provisions, or cross-licensing arrangements, if any, are not part of the public record — a common outcome in food technology IP disputes where commercial relationships and product roadmaps are commercially sensitive.

The Verdict & Legal Analysis

Outcome

The action was dismissed with prejudice on July 19, 2024, pursuant to a joint stipulation filed by all parties following a global confidential settlement executed on July 17, 2024. No court-determined damages, royalty awards, or injunctive relief were issued, and no judicial ruling on the merits of the declaratory judgment claims or Emergy’s counterclaims was rendered. The dismissal with prejudice extinguishes all claims, counterclaims, and defenses raised by Better Meat Company, Augustus Pattillo, Emergy, Inc., Paul Vronsky, and Bond Capital Management LP in connection with this action.

Verdict Cause Analysis

The declaratory judgment posture and confidential settlement structure reflect several important legal and strategic dynamics at play in this dispute:

• Better Meat Company filed as the declaratory judgment plaintiff, indicating it faced a credible threat of infringement assertion from Emergy regarding US11058137B2 prior to or concurrent with commercialization of its competing mycoprotein products.
• The naming of Bond Capital Management LP and investor Paul Vronsky as defendants is procedurally notable and may reflect allegations that these parties participated in or directed the IP enforcement strategy or had an interest in the patent rights at issue.
• Counter-defendant Augustus Pattillo’s inclusion — not listed in the original party data but referenced in the dismissal stipulation — suggests the dispute had a personnel or trade secret dimension, potentially involving former employees or co-founders with knowledge of the patented technology.
• The resolution by confidential global settlement after nearly three years of litigation, without any published ruling on claim construction or validity, means the substantive legal questions underlying this dispute remain unresolved and potentially live for future proceedings against third parties.

Legal Significance

1. 1. Because the case settled before any claim construction order or summary judgment ruling, US11058137B2 retains its full presumption of validity and no judicial interpretation of its claims has been placed into the public record, leaving the patent’s scope legally intact against non-parties.
2. 2. The involvement of investor defendants Bond Capital Management LP and Paul Vronsky may signal an emerging litigation tactic in the food tech sector where IP plaintiffs seek to pierce the corporate veil or hold financing entities accountable for alleged IP-based competitive harm.
3. 3. The dismissal with prejudice prevents any re-assertion of these specific claims between these parties, but Emergy retains full rights to assert US11058137B2 against other mycoprotein competitors, making this patent a continuing risk for the broader alternative protein industry.

Strategic Takeaways

For Patent Attorneys:

• When advising food tech clients facing potential infringement assertions on core process patents, consider the offensive declaratory judgment posture as a means to force settlement negotiations and neutralize enforcement threats before commercialization.
• The inclusion of investor and individual defendants in this action underscores the need to counsel VC-backed patentees that their principals may face personal exposure in declaratory judgment actions, particularly where investors are alleged to control enforcement decisions.
• Given the absence of any public claim construction ruling, attorneys conducting FTO analysis for mycoprotein clients must rely on prosecution history and examiner interviews for US11058137B2 rather than judicial guidance, increasing analytical uncertainty.
• The confidential global settlement structure here is a model for resolving multi-party food tech IP disputes where the parties have ongoing commercial interests and wish to avoid precedent-setting judicial rulings on patent validity or scope.

For IP Professionals:

• In-house IP teams at alternative protein companies should monitor US11058137B2 and Emergy’s related patent family closely, as the patent’s validity and scope remain judicially untested and it can be enforced against new market entrants at any time.
• The settlement here — reached after nearly three years of litigation — highlights the value of early freedom-to-operate analysis and pre-litigation licensing outreach in the food technology sector, where patent thickets are rapidly forming around core fermentation and biomass processing techniques.

For R&D Teams:

• R&D teams developing fungal fermentation or mycoprotein-based ingredients should commission a detailed FTO analysis against US11058137B2 before entering clinical or commercial development stages, as the patent covers foundational production methods that are difficult to design around without early planning.
• Engineering teams working on whole-cut meat alternative textures achieved through fungal biomass processing should document design-around decisions contemporaneously, as the lack of public claim construction guidance for this patent means the boundaries of its protection remain unpredictable.